VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 20, 2009) - In continuing efforts to advance the field of Protein Modification Technologies, Advanced Proteome Therapeutics (“APT”) (TSX VENTURE: APC) has filed what it believes is a landmark patent application this month on inventions related to its Swift Linkage Multivalent Technology (SMLT). This Patent, along with previous discoveries, represents a milestone in the company’s development and is a significant step toward commercialization.
Protein therapeutics is the fastest growing segment of the pharmaceutical market, with sales projected to be in the 75 billion dollar range by 2013. The Company feels it is well positioned, by virtue of discoveries related to SLMT, to capitalize on this growing market with its own internal projects as well as those of potential partners.
This advanced technology is currently being applied internally to protein targets aimed at treating cancer, Crohn’s disease, arthritis, obesity, atherothrombosis and plaque rupture. In conjunction with the Company’s internal progress, this patent filing allows the Company to foster relationships with potential partners, and/or customers that desire to utilize APT technology to further the development of their own programs.
The Company believes that the technology expands commercial opportunities for APT in certain subfields of protein therapeutics that have been especially challenging, providing APT with a competitive edge, and further validating its corporate strategy.
About Swift Linkage Multivalent Technology - Invented by APT to expand the repertoire of entities that can be rapidly linked to protein sites to generate products for development, the technology enables the rapid attachment of a desired entity to a modified site on a protein surface site-specifically, and to the fullest extent. SMLT has been demonstrated in several instances in APT programs to be capable of providing homogeneous products and may offer distinct technological advantages in the synthesis and manufacturing process of new protein therapeutics.
About Advanced Protein Therapeutics - APT is a pioneer and leader in the development of Protein Modification Technology which is directed toward altering proteins to improve their therapeutic and industrial potential. APT has created a broad platform technology applicable to a large variety of protein-based products to treat multiple areas of unmet medical need. The Company is applying its technology to the two fastest growing areas of therapeutics and diagnostics, Protein Drugs, and Personalized Medicine, respectively.
The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.
Contacts:
Gale Capital Corporation
604.200 0103, ext. 272 (APC)
apc@galecapital.com
